Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year...
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers....
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and
